Search clinical trials for: GCFLU® Influenza vaccine (Split virion, Inactivated)

Total 442 results

Institute of Clinical Research and Clinical Trial...
Green Cross Corporation

Completed

Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old

Influenza, Human

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of the Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infections

Belgium, Germany, Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

Influenza | Myxovirus Infection | Orthomyxovirus Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
Butantan Institute
Fundação Butantan

Recruiting

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Influenza, Human

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Tel-Aviv Sourasky Medical Center

Unknown

Influenza Vaccination in Fibromyalgia Patients

Fibromyalgia Syndrome

Israel
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Influenza A Virus Infection

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Australia, New Zealand
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

Switzerland, United Kingdom
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

Influenza | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Italy, Belgium, France, Lithuania
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Czech Republic, Lithuania, Belgium
Hualan Biological Bacterin Co. Ltd.

Completed

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

GCP

China
Sinovac Biotech Co., Ltd

Completed

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Seasonal Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

Influenza

Taiwan
Jiangsu Province Centers for Disease Control and...
Jiangsu Jindike Biotechnology Co., Ltd.

Completed

A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

Influenza

China
Wayne Sullender, M.D.
All India Institute of Medical Sciences, New Delhi; Centers for Disease Control...

Completed

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Influenza

India
Sanofi

Completed

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months

Influenza

Korea, Republic of
British Columbia Centre for Disease Control

Completed

Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity (TITRE)

Influenza

Canada
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old

Influenza, Human | Vaccination; Infection | Vaccines

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

Influenza | Orthomyxoviridae Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Orthomyxovirus Infections

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Describe the Safety and Immunogenicity of Fluzone®

Influenza

United States
Johns Hopkins Bloomberg School of Public Health
Columbia University; Sanofi Pasteur, a Sanofi Company; Institute of Epidemiology... and other collaborators

Completed

Pregnancy, Arsenic and Immune Response (PAIR)

Influenza | Vaccine Response Impaired | Micronutrient Deficiency | Arsenic--Toxicology | Immunologic Disorders Complicating Pregnancy

Bangladesh
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects

Influenza | Orthomyxoviridae Infections

France
St. Petersburg Research Institute of Vaccines and...

Recruiting

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Vaccine Reaction | Influenza | Influenza, Human | Influenza Viral Infections

Russian Federation
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)

Influenza

France
Dalhousie University
Mount Sinai Hospital, Canada; IWK Health Centre; MCM Vaccines B.V.

Completed

Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine

Influenza

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Spain, France, Lithuania, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Influenza

Russian Federation
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
St. Petersburg Research Institute of Vaccines and...

Completed

Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra

Influenza

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

France
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults

Influenza | Swine-origin A/H1N1 Influenza

France

3

Subscribe